Compare KB Financial Group, Inc. (KB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Novartis AG — how do they compare? KB Financial Group, Inc. trades at $121.96 (market cap $44.15B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 6.2× KB Financial Group, Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Novartis AG for 82 Days on average.
| KB | NVS | |
|---|---|---|
Market Cap | $44.15B | $274.00B |
Volume | 131,395 | 1,852,137 |
Sector | Financials | Health |
52-Week High | $132.88 | $168.62 |
52-Week Low | $77.50 | $121.80 |
Typical Hold Time | 33 Days | 82 Days |
Enterprise Value | $215.53T | $315.32B |
Dividend Yield | 2.65% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock exhibits neutral technical signals while maintaining strong fundamental performance with consistent earnings beats and improving profitability. Recent quarterly results exceeded expectations, with Q2 2026 EPS of $3.79 beating estimates of $3.51. The company demonstrates solid revenue growth, climbing from $17.77T in 2022 to $21.23T in 2025, with net income margins expanding to 27.47%.
KB presents an attractive value proposition with a P/E of 9.92 and P/B of 0.97, trading below book value. Analyst sentiment is mixed with 33% buy ratings but strong institutional interest. Key risks include banking sector volatility and interest rate sensitivity, while opportunities lie in South Korea's outperforming market and the company's expanding non-banking activities driving fee income growth.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
